Get the Stockscreener App
9.83
1.34%
0.16
Delcath Systems Inc stock is traded at $9.83, with a volume of 36,428.
It is up +1.34% in the last 24 hours and up +7.93% over the past month.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$9.67
Open:
$10
24h Volume:
36,428
Relative Volume:
0.08
Market Cap:
$338.00M
Revenue:
$85.23M
Net Income/Loss:
$2.70M
P/E Ratio:
156.53
EPS:
0.0628
Net Cash Flow:
$20.97M
1W Performance:
+2.73%
1M Performance:
+7.93%
6M Performance:
-11.71%
1Y Performance:
-5.68%
1-Day Range:
$9.76
$10.05
1-Week Range:
$9.29
$10.05
52-Week Range:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
9.81 | 333.18M | 85.23M | 2.70M | 20.97M | 0.0628 |
ABT
Abbott Laboratories
|
103.03 | 176.95B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
339.19 | 127.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.64 | 110.95B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.77 | 91.93B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.55 | 46.61B | 6.07B | 1.06B | 1.34B | 1.8063 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Implied Volatility Soars for Delcath Systems Options - Bitget
Implied Volatility Surging for Delcath Systems Stock Options - TradingView
Is Delcath Systems Inc a strong candidate for buy and holdWeekly Trade Report & Verified Technical Signals - baoquankhu1.vn
Delcath Systems (DCTH) Gains Recognition in Clinical Guidelines - GuruFocus
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma - BioSpace
Delcath therapy included in European uveal melanoma guidelines By Investing.com - Investing.com India
Delcath therapy included in European uveal melanoma guidelines - Investing.com
Bear Alert: Is Delcath Systems Inc a strong candidate for buy and holdMarket Weekly Review & Growth Focused Stock Reports - baoquankhu1.vn
Aug Levels: Is Delcath Systems Inc a strong candidate for buy and holdShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
EBIT per share of Delcath Systems, Inc. – MUN:DV3R - TradingView
DCTH PE Ratio & Valuation, Is DCTH Overvalued - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
DV3R.SG,0P0000X679,0 (DV3R.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2025 earnings call transcript - MSN
Responsive Playbooks and the DCTH Inflection - Stock Traders Daily
Delcath Systems Inc. (US24661P8077.SG) Balance Sheet - Yahoo! Finance Canada
Delcath (NASDAQ: DCTH) seeks approval to expand 2020 equity incentive plan - Stock Titan
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting - BioSpace
DV3R.SG,0P0000X679,0 (DV3R.SG) stock price, news, quote and history - Yahoo Finance UK
Delcath Systems (DCTH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Decliners Report: What are the future prospects of Delcath Systems IncProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Are options traders betting on a big move in Delcath Systems stock? - MSN
Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030 - GlobeNewswire
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 2025 Delcath Systems Inc Earnings Call Transcript - GuruFocus
Risk Analysis: Is Delcath Systems Inc backed by strong institutional buyingForecast Cut & Daily Stock Trend Watchlist - baoquankhu1.vn
Market Catalysts: What is BDSXs 5 year growth outlookTrade Analysis Report & Safe Entry Zone Tips - baoquankhu1.vn
Understanding the Setup: (DCTH) and Scalable Risk - Stock Traders Daily
FRA:DV3R PB Ratio: 2.85 — 49% Below Median - GuruFocus
Form 13G DELCATH SYSTEMS For: 20 March By Investing.com - Investing.com Australia
Daniel Kaufman reports 5.08% stake in Delcath Systems (DCTH) - Stock Titan
Divisadero Street Capital Management LP Invests $5.12 Million in Delcath Systems, Inc. $DCTH - MarketBeat
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $250,000 from Inve - Yahoo
The Technical Signals Behind (DCTH) That Institutions Follow - Stock Traders Daily
Delcath Systems Charts Profitable Path Amid Heavy Investment - The Globe and Mail
Delcath Systems Q3 2025 Earnings Preview - MSN
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates - MSN
Can Delcath Systems Inc expand into new marketsQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Insider Buying: Sandra Pennell Acquires Shares of Delcath Systems Inc (DCTH) - GuruFocus
Delcath Systems (DCTH) CFO purchases 5,533 common shares at $9.04 - Stock Titan
Fundamentals Check: Is Delcath Systems Inc a strong candidate for buy and holdMarket Performance Report & Accurate Intraday Trading Signals - baoquankhu1.vn
Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH - MarketBeat
Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology - Yahoo Finance
HC Wainwright Lowers Earnings Estimates for Delcath Systems - MarketBeat
Delcath announces publication of liver cancer treatment trial - Investing.com
Delcath announces publication of liver cancer treatment trial By Investing.com - Investing.com Canada
Delcath Highlights CHOPIN Phase 2 Results in Uveal Melanoma - TipRanks
Insider Buying: Gerard Michel Acquires Additional Shares of Delc - GuruFocus
CHOPIN uveal melanoma trial data in Lancet boosts Delcath (Nasdaq: DCTH) - Stock Titan
[Form 4] DELCATH SYSTEMS, INC. Insider Trading Activity - Stock Titan
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):